Drugs / Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum
also known as
Collagenase · Santyl · AA4500 · Xiaflex · CCH · Clostridial Collagenase · Collagenase clostridium histolyticum-aaes · AK160 · +8 more
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed familial Dupuytren contracture 1 milestone | |||||
| Filed | Other | XIAFLEX | familial Dupuytren contracture | 2013-07-16 | “A XIAFLEX submission has been filed for approval in Australia for the treatment of Dupuytren's contracture.” sobi.com ↗ |
| Filed Peyronie disease 1 milestone | |||||
| Filed | EU (EMA) | Xiapex | Peyronie disease | 2014-06-25 | “Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) with the European Medicines Agency (EMA)” sobi.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (3) | US (FDA) | XIAFLEX | — | 2013-12-06 – 2015-05-15 | fda.gov ↗ |
| Approved | EU (EMA) | Xiapex | — | 2011-02-28 | europa.eu ↗ |
| Approved | US (FDA) | SANTYL | — | 1965-06-04 | fda.gov ↗ |
Trials 57
1964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07693569 | Sep 2026 → May 2031 expected | — | The University of Texas Health Science Center, Houston | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07693556 | Sep 2026 → May 2031 expected | — | The University of Texas Health Science Center, Houston | Not yet recruiting | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT03675685 | Sep → Nov 2018 | panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 1 | NCT01518907 | Jan → Dec 2012 | cellulitis, panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 1 | NCT01271335 | Nov 2009 → Sep 2011 | arterial occlusion | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 1 | NCT00528931 | Sep → Dec 2007 | palmar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00261209 | Jan 2005 → Jan 2008 | extensor tendons of finger anomalies | Stony Brook University | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT06169319 | Jan → Sep 2024 | plantar fasciitis | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT04236635 | Dec 2019 → Sep 2020 | — | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT03329989 | Nov 2017 → Sep 2018 | cellulitis, panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT02942160 | Oct 2016 → Jun 2018 | cellulitis, panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT02724644 | Feb → Sep 2016 | cellulitis, panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT02193828 | Jul → Dec 2014 | palmar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | Mixed |
| Phase 2 | NCT01753180 | Apr 2014 → Dec 2015 | arterial occlusion | Matrizyme Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02006719 | Nov 2013 → Dec 2014 | frozen shoulder | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT01987986 | Oct 2013 → Aug 2014 | panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT00261144 | Feb 2013 → Feb 2014 | cellulitis | Stony Brook University | Unknown | No outcome recorded |
| Phase 2 | NCT01613313 | May 2012 → Sep 2013 | lipoma | Zachary Gerut | Completed | No outcome recorded |
| Phase 2 | NCT01483963 | Nov 2011 → Feb 2013 | frozen shoulder | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT01430169 | Sep → Nov 2011 | Peyronie disease | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT01237964 | Mar → Apr 2011 | — | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00755222 | Aug 2008 → Dec 2009 | Peyronie disease | Endo USA Inc., a Keenova Therapeutics Company | Completed | Mixed |
| Phase 2 | NCT00261196 | Jan 2006 → Jan 2009 | frozen shoulder | Stony Brook University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00004409 | Aug 1995 → Apr 2004 | palmar fibromatosis | State University of New York | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00701974 | Feb 2008 | ulcer disease | Azidus Brasil | Suspended | No outcome recorded Stop: Business |
| Phase 314 trials · 5 met primary | ||||||
| Phase 3 | NCT01776892 | May 2013 → Mar 2014 | palmar fibromatosis | University of Alberta | Withdrawn | No outcome recorded |
| Phase 3 | NCT01685437 | Sep 2012 → Dec 2013 | Peyronie disease | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 3 | NCT01674634 | Sep 2012 → Jul 2013 | palmar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 3 | NCT01588353 | May 2012 → Jan 2014 | palmar fibromatosis | Asahi Kasei Therapeutics Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01407068 | Sep 2011 → Feb 2012 | palmar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 3 | NCT01243411 | Nov 2010 → Aug 2012 | Peyronie disease | Endo USA Inc., a Keenova Therapeutics Company | Completed | Met primary |
| Phase 3 | NCT01221623 | Oct 2010 → Mar 2012 | Peyronie disease | Endo USA Inc., a Keenova Therapeutics Company | Completed | Met primary |
| Phase 3 | NCT01221597 | Sep 2010 → Apr 2012 | Peyronie disease | Endo USA Inc., a Keenova Therapeutics Company | Completed | Met primary |
| Phase 3 | NCT00528424 | Dec 2007 → Nov 2008 | palmar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 3 | NCT00528840 | Oct 2007 → Oct 2008 | palmar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 3 | NCT00533273 | Aug 2007 → Sep 2008 | palmar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | Met primary |
| Phase 3 | NCT00528606 | Aug 2007 → Apr 2008 | palmar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | Met primary |
| Phase 3 | NCT00260429 | Jun 2003 → Aug 2005 | palmar fibromatosis | Stony Brook University | Completed | No outcome recorded |
| Phase 3 | NCT00014742 | ? → Apr 2004 | palmar fibromatosis | State University of New York | Completed | No outcome recorded |
| Phase 417 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT06649539 | Oct 2024 → Oct 2029 expected | Peyronie disease | Charitable Union for the Research and Education of Peyronie's Disease | Recruiting | No outcome recorded |
| Phase 4 | NCT05777031 | Oct 2023 → Jan 2027 expected | Peyronie disease, psychosexual disorder | University of Miami | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05108558 | Sep 2021 → Dec 2025 overdue | Peyronie disease | Charitable Union for the Research and Education of Peyronie's Disease | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05026216 | Mar → Aug 2021 | cellulitis | DMR Research, PLLC | Completed | No outcome recorded |
| Phase 4 | NCT03815331 | Jan 2019 → Dec 2020 | Peyronie disease | Men's Health Boston | Completed | No outcome recorded |
| Phase 4 | NCT03767452 | Oct 2018 → Dec 2019 | Peyronie disease | Manhattan Medical Research Practice, PLLC | Unknown | No outcome recorded |
| Phase 4 | NCT03406338 | Mar 2018 → Sep 2024 overdue | palmar fibromatosis | Region Skane | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03192020 | Sep 2017 → May 2026 overdue | palmar fibromatosis | Tampere University | Active not recruiting | Met primary |
| Phase 4 | NCT02716519 | Aug 2016 → Dec 2018 | decubitus ulcer, ulcer of lower limbs | Smith & Nephew, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT02718625 | Aug 2016 → Mar 2017 | decubitus ulcer | Smith & Nephew, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT02581488 | Oct 2015 → Jan 2017 | chronic ulcer of skin | Smith & Nephew, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02111291 | Apr 2014 → Dec 2015 | ulcer of lower limbs | Healthpoint | Completed | No outcome recorded |
| Phase 4 | NCT01498640 | Mar 2012 → Oct 2013 | palmar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 4 | NCT01668030 | Feb 2012 → Nov 2013 | — | University of Louisville | Completed | Missed primary |
| Phase 4 | NCT01450397 | Mar 2011 → Jan 2012 | palmar fibromatosis | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 4 | NCT01197898 | Dec 2010 → Apr 2012 | ulcer of lower limbs | Healthpoint | Completed | No outcome recorded |
| Phase 4 | NCT01265420 | Dec 2010 → Feb 2014 | palmar fibromatosis | Indiana Hand to Shoulder Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01208220 | Jun 2010 → Dec 2011 | decubitus ulcer | Louisiana State University Health Sciences Center Shreveport | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy25 trials | ||||||
| Phase 1 | NCT04963829 Comparator | Feb → Nov 2018 | chronic ulcer of skin, ulcer disease | Universidade do Vale do Sapucai | Completed | No outcome recorded |
| Phase 1 | NCT02131961 Background | Oct 2014 → Jun 2015 | ulcer of lower limbs | University of Miami | Completed | No outcome recorded |
| Phase 2 | NCT04580303 Comparator | Oct 2020 → Aug 2021 | cellulitis, cutis laxa, panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT03588130 Comparator | Dec 2019 → Dec 2021 | ulcer of lower limbs | MediWound Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03632993 Comparator | Sep 2018 → Jan 2019 | — | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT02249052 Comparator | Aug 2014 → Apr 2016 | lipoma | Gerut, Zachary, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT04874870 Comparator | Jul 2021 → Dec 2023 | palmar fibromatosis | Foundation for Orthopaedic Research and Education | Completed | No outcome recorded |
| Phase 3 | NCT03428750 Comparator | Feb → Sep 2018 | panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 3 | NCT02725528 Comparator | Jul 2017 → Dec 2021 | palmar fibromatosis | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT02004626 Comparator | Jan → Jun 2015 | decubitus ulcer | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02267460 Comparator | Oct 2014 → Oct 2015 | Peyronie disease | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 4 | NCT05309525 Comparator | Apr → Sep 2022 | — | Luxurgery | Completed | No outcome recorded |
| Phase 4 | NCT04786106 Comparator | Dec 2020 → Feb 2027 expected | Peyronie disease | Charitable Union for the Research and Education of Peyronie's Disease | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03000114 Comparator | Jan 2016 → Jan 2021 | palmar fibromatosis | University of Calgary | Unknown | No outcome recorded |
| Phase 4 | NCT02673229 Comparator | Sep 2013 → Dec 2018 | — | University of Kansas Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01516463 Comparator | Mar 2012 → Jun 2013 | — | Healthpoint | Withdrawn | No outcome recorded |
| Phase 4 | NCT01408277 Comparator | Aug 2011 → Nov 2012 | ulcer of lower limbs | Healthpoint | Completed | No outcome recorded |
| Phase 4 | NCT01226121 Comparator | Dec 2010 → Dec 2012 | palmar fibromatosis | Indiana Hand to Shoulder Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01143727 Comparator | Jul 2010 → Oct 2011 | ulcer of lower limbs | Healthpoint | Completed | No outcome recorded |
| Phase 4 | NCT01143714 Comparator | Jun 2010 → Apr 2012 | ulcer of lower limbs | Healthpoint | Completed | No outcome recorded |
| Phase 4 | NCT01056198 Comparator | Feb 2010 → Aug 2011 | ulcer of lower limbs | Healthpoint | Completed | No outcome recorded |
| — | NCT06065436 Background | Jan 2024 → Dec 2026 expected | Peyronie disease, erectile dysfunction | Mayo Clinic | Recruiting | No outcome recorded |
| — | NCT05646602 Background | Mar 2023 → Dec 2024 | Peyronie disease, erectile dysfunction | Mayo Clinic | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT03722485 Comparator | Dec 2018 → Apr 2022 | — | KCI USA, Inc | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02482948 Comparator | Jun 2015 → Mar 2017 | ulcer disease | Integra LifeSciences Corporation | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2026-08-03 | Mallinckrodt | Results Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology gcs-web.com ↗ |
| 2026-08-03 | Endo USA Inc., a Keenova Therapeutics Company | Results Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology mediaroom.com ↗
This reinforces that pain and disease duration, while important factors, should not be the sole determinants of treatment timing, but treatment decisions should be grounded in a comprehensive clinical assessment and the evolving understanding of Peyronie's disease. |
| 2026-07-08 | Mallinckrodt | Results Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis gcs-web.com ↗
The pivotal trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in pain versus placebo, as measured by the Average Daily Pain Intensity on the Numeric Rating Scale (NRS). |
| 2026-07-08 | Endo USA Inc., a Keenova Therapeutics Company | Results Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis mediaroom.com ↗
Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic medical condition that causes nodules composed primarily of excess collagen to form in the connective tissue that supports the arch of the foot. |
| 2026-05-15 | Mallinckrodt | Results Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting gcs-web.com ↗
The data to be presented will highlight that the clinical effectiveness and safety of XIAFLEX (collagenase clostridium histolyticum) in patients with ventral curvature are consistent with outcomes observed in patients with other clinical presentations of Peyronie's disease. |
| 2026-05-15 | Endo USA Inc., a Keenova Therapeutics Company | Results Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting mediaroom.com ↗ |
| 2026-03-31 | Endo USA Inc., a Keenova Therapeutics Company | Results Keenova Announces Unaudited Fourth Quarter 2025 Financial Results mediaroom.com ↗
Hammer Toe Trial Meets Primary Safety Endpoint and Secondary, Exploratory Efficacy Endpoints |
| 2026-03-03 | Mallinckrodt | Results Keenova Publishes XIAFLEX® (collagenase clostridium histolyticum) Analysis in Journal of Hand Surgery Global Online gcs-web.com ↗
Findings suggest XIAFLEX may offer an alternative to repeat surgery and add to existing insights on recurrence management. |
| 2026-03-03 | Endo USA Inc., a Keenova Therapeutics Company | Results Keenova Publishes XIAFLEX® (collagenase clostridium histolyticum) Analysis in Journal of Hand Surgery Global Online mediaroom.com ↗
Findings suggest XIAFLEX may offer an alternative to repeat surgery and add to existing insights on recurrence management. |
| 2026-02-24 | Mallinckrodt | Results Keenova Unveils Clinical Data from Phase 2 Plantar Fibromatosis Study at the ACFAS Annual Meeting gcs-web.com ↗
Patients receiving initial treatment or re‑treatment with CCH demonstrated a safety profile consistent with the earlier phase 2 study. |
| 2026-02-24 | Endo USA Inc., a Keenova Therapeutics Company | Results Keenova Unveils Clinical Data from Phase 2 Plantar Fibromatosis Study at the ACFAS Annual Meeting mediaroom.com ↗
Patients receiving initial treatment or re‐treatment with CCH demonstrated a safety profile consistent with the earlier phase 2 study. |
| 2025-05-13 | MediWound Ltd | Results MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers mediwound.com ↗
Compared to SANTYL, EscharEx achieved faster and more effective debridement and promoted healthier granulation tissue, both key to optimal wound bed preparation. |
| 2024-02-12 | MediWound Ltd | Results MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study mediwound.com ↗ |
| 2017-06-30 | Sobi, Inc. | Regulatory Xiapex® gets recommendation to be made available on National Health Service in England sobi.com ↗ |
| 2015-01-30 | Sobi, Inc. | Regulatory Xiapex approved by the EU Commission for the treatment of Peyronie's disease sobi.com ↗
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the EU Commission has approved Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. |
| 2014-06-25 | Sobi, Inc. | Regulatory Sobi files for EU approval of Xiapex for Peyronies disease sobi.com ↗
Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc.today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. |
| 2014-04-07 | Sobi, Inc. | Regulatory Sobi becomes market authorisation holder for Xiapex in Europe sobi.com ↗
Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on 3 April, 2014. |
All press releases naming this drug 20 releases
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 85 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | collagenase clostridium histolyticum | “The primary objective of this pilot study is to determine whether testosterone therapy offers increased efficacy of Xiaflex® (collagenase clostridium histolyticum) in subjects...” NCT03815331 ↗36“Collagenase clostridium histolyticum (CCH; Xiaflex, Auxilium Pharmaceuticals, Inc., Chesterbrook, PA, USA) is a Food and Drug Administration-approved, intralesional treatment...” PMID 25388099 ↗ Nov 2014 “Combined data from the collagenase Clostridium histolyticum phase 3 study program, IMPRESS (Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) I and...” PMID 26199168 ↗ Jul 2015 “Injection of collagenase clostridium histolyticum, an office-based, nonsurgical option, may reduce joint contractures caused by Dupuytren's disease.” PMID 19726771 ↗ Sep 2009 “Efficacy of a Novel Collagenase Clostridium Histolyticum Protocol for Peyronie's Disease Among Prior Non-responders” NCT05108558 ↗ “Collagenase clostridium histolyticum will be used to treat participants in this arm of the study.” NCT01776892 ↗ “enzyme, collagenase clostridium histolyticum, xiaflex” NCT02725528 ↗ “EN3835 0.84mg (Collagenase Clostridium Histolyticum)” NCT03428750 ↗ “AA4500 collagenase clostridium histolyticum” NCT01407068 ↗ |
| Known as | AA4500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00755222 ↗ |
| Known as | AK160 | “AK160 (Collagenase Clostridium Histolyticum) 0.58 mg” NCT01588353 ↗ |
| Known as | CCH | “Collagenase clostridium histolyticum (CCH; Xiaflex, Auxilium Pharmaceuticals, Inc., Chesterbrook, PA, USA) is a Food and Drug Administration-approved, intralesional treatment...” PMID 25388099 ↗ Nov 20147“Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP.” NCT03632993 ↗ “OBJECTIVE: To assess collagenase clostridium histolyticum-aaes (CCH) for the treatment of cellulite.” PMID 33840781 ↗ May 2021 “Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)” NCT04786106 ↗ “collagenase clostridium histolyticum (CCH) injection” PMID 28854973 ↗ Aug 2017 “Collagenase Clostridium Histolyticum (CCH)” NCT05777031 ↗ “Collagenase Clostridium Histolyticum (CCH)” NCT06169319 ↗ “CCH (collagenase clostridium histolyticum)” NCT03675685 ↗ |
| Known as | CCO | “Enzymatic debridement with clostridial collagenase ointment (CCO) can be used to remove necrotic tissue from wounds.” PMID 25767565 ↗ Feb 2015 |
| Known as | Clostridial Collagenase | “Clinical Outcomes for Diabetic Foot Ulcers Treated With Clostridial Collagenase (SANTYL®) Ointment or With a Comparator Product Containing Silver” NCT02581488 ↗4“Enzymatic debridement with clostridial collagenase ointment (CCO) can be used to remove necrotic tissue from wounds.” PMID 25767565 ↗ Feb 2015 “Clostridial Collagenase (Santyl®) Ointment” NCT02111291 ↗ |
| Known as | Clostridial collagenase for injection (AA4500) | “Clostridial collagenase for injection (AA4500)” NCT00755222 ↗ |
| Known as | Collagenase | “A Vehicle-Controlled Study to Determine the Effect of Four Weeks of Debridement With Collagenase Santyl Ointment (Santyl) on the Healing of Diabetic Foot Ulcers” NCT01143714 ↗21“Unfortunately, to date there has been no research examining the potential benefits of using collagenase in patients with facial burn injuries.” NCT01668030 ↗ “Collagenase” NCT00261144 ↗ |
| Known as | Collagenase clostridium histolyticum-aaes | “Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenases AUX-I and AUX-II, in an approximate 1:1 mass ratio, which are isolated and purified from...” NCT05026216 ↗2“OBJECTIVE: To assess collagenase clostridium histolyticum-aaes (CCH) for the treatment of cellulite.” PMID 33840781 ↗ May 2021 |
| Known as | EN3835 | “EN3835 0.84mg (Collagenase Clostridium Histolyticum)” NCT03329989 ↗ |
| Known as | IRUXOL | “collagenase (IRUXOL)” NCT00701974 ↗ |
| Known as | Kollagenase | “collagenase (Kollagenase)” NCT00701974 ↗ |
| Known as | Qwo | “To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Clostridium Histolyticum-aases, Qwo, for the Treatment of Mild to Moderate Cellulite in Adult Females...” NCT05026216 ↗ |
| Known as | Santyl | “A Vehicle-Controlled Study to Determine the Effect of Four Weeks of Debridement With Collagenase Santyl Ointment (Santyl) on the Healing of Diabetic Foot Ulcers” NCT01143714 ↗10“This study is designed to compare SANTYL® versus hydrogel (SoloSite®) in the treatment of pressure ulcers for participants in a long-term care facility.” NCT02718625 ↗ “Clinical Outcomes for Diabetic Foot Ulcers Treated With Clostridial Collagenase (SANTYL®) Ointment or With a Comparator Product Containing Silver” NCT02581488 ↗ “Evaluate the effectiveness of Collagenase Santyl ointment when used in conjunction with NPWT for the treatment of chronic pressure ulcers” NCT01208220 ↗ “Santyl (Enzymatic debridement) or commercially approved Hydrogel” NCT03588130 ↗ “Biological: Collagenase Santyl Ointment” NCT01197898 ↗ “Collagenase SANTYL® Ointment” NCT02111291 ↗ |
| Known as | Xiaflex | “XIAFLEX is an FDA-Approved collagenase for treatment of Dupuytren's contracture with a palpable cord in the fingers, and Peyronie's disease in the penile tissue.” NCT07693556 ↗8“XIAFLEX is an FDA-Approved collagenase for treatment of Dupuytren's contracture with a palpable cord in the fingers, and Peyronie's disease in the penile tissue.” NCT07693569 ↗ “Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]” NCT03192020 ↗ “Xiaflex (FDA approved collagenase)” NCT01237964 ↗ |
| Known as | Xiaflex( Collagenase Clostridium Histolytiucm) | “Xiaflex( Collagenase Clostridium Histolytiucm)” NCT01237964 ↗ |
| Known as | XIAFLEX, Collagenase Clostridium Histolyticum | “XIAFLEX, Collagenase Clostridium Histolyticum” NCT02249052 ↗ |
| Modality | Protein / enzyme biologic | “Biological: collagenase clostridium histolyticum” NCT00528840 ↗ |
| Route | Other | “Patients receive a single collagenase injection into the target finger cord on day 0.” NCT00014742 ↗ |